IDO1 and sarcoma: Treatment of sarcoma cells with HDAC inhibitors reduced the expression of PD-L1, PD-L2, ornithine decarboxylase (ODC), and indoleamine-pyrrole 2,3-dioxygenase (IDO-1), and increased expression of the class I MHC protein MHCA.